Patient preferences in PACES clinical three treatment (six sequence) crossover clinical trials in all completers and protocol adherent patients.
| PACES-a | PACES-b | |||
|---|---|---|---|---|
| All completers† | Protocol adherent | All completers† | Protocol adherent | |
| Values are the number (%) of patients unless otherwise stated. | ||||
| *Results are from a conditional logistic regression model with period and treatment as fixed effects and patient as the strata variable; †all completers are patients in the intention to treat group who provided a response for patient preference. | ||||
| Celecoxib v acetaminophen | ||||
| Prefer celecoxib | 91 (52.6) | 66 (57.4) | 95 (49.5) | 84 (52.8) |
| Prefer acetaminophen | 42 (24.3) | 24 (20.9) | 62 (32.3) | 51 (32.1) |
| No preference | 40 (23.1) | 25 (21.7) | 35 (18.3) | 24 (15.1) |
| OR (SE)* | 2.07 (1.18) | 2.47 (1.22) | 1.47 (1.16) | 1.64 (1.18) |
| p Value* | <0.001 | <0.001 | 0.009 | 0.002 |
| Celecoxib v placebo | ||||
| Prefer celecoxib | 71 (52.2) | 54 (55.7) | 76 (56.7) | 62 (59.0) |
| Prefer placebo | 31 (22.8) | 24 (24.7) | 32 (23.9) | 23 (21.9) |
| No preference | 34 (25.0) | 19 (19.6) | 26 (19.4) | 20 (19.0) |
| OR (SE)* | 2.51 (1.20) | 2.48 (1.24) | 2.47 (1.19) | 2.60 (1.23) |
| p Value* | <0.001 | <0.001 | <0.001 | <0.001 |
| Acetaminophen v placebo | ||||
| Prefer acetaminophen | 31 (37.4) | 22 (36.1) | 41 (47.7) | 29 (44.6) |
| Prefer placebo | 23 (27.7) | 18 (29.5) | 21 (24.4) | 17 (26.2) |
| No preference | 29 (34.9) | 21 (34.4) | 24 (27.9) | 19 (29.2) |
| OR (SE)* | 1.21 (1.22) | 1.01 (1.26) | 1.68 (1.21) | 1.59 (1.24) |
| p Value* | 0.340 | 0.977 | 0.007 | 0.033 |